Cancer genomic testing is a newer field of genetics which is used to diagnose the different type of cancer. Cancer genomic testing is completely different from genetic testing, because during genomic testing all of patient gene is being tested. Alteration or mutation of genes is the key cancer causing factor. During the cancer genomic testing, the alteration or mutation of gene is being tested. Cancer genomic testing is typically done by collecting the blood sample of the patient. Cancer genomic testing helps to identify the risk of cancer for particular patient. Moreover, cancer genomic testing able to predict the behavior of tumor. Cancer genomic testing also helps to understand metastasize of cancer and type of mutation. Cancer genomic testing is more widely performed for the detection of breast and lung cancer.
Request Free Sample Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=3999
Cancer Genomic Testing Market: Segmentation
Tentatively, the global cancer genomic testing market can be segmented on the basis of cancer type, end user and geography.
Based on cancer type, the global cancer genomic testing market is segmented as:
Breast Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Stomach Cancer
Others
Based on distribution channel, the global cancer genomic testing market is segmented as:
Hospitals
Diagnostic Laboratories
Cancer Research Centers
Academic and Research Institutes
Specialized Clinics
Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=3999
Report on Cancer Genomic Testing includes the regional analysis for
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Cancer Genomic Testing Market: Key Players
Some of the key players operating in the global Cancer Genomic Testing Market are Myriad Genetics, Inc., CENTOGENE AG, Color Genomics, Quest Diagnostics, Inc., 23andMe Inc., Gene by Gene Ltd., Laboratory Corporation of America Holdings, Positive Bioscience, Bio Rad Laboratories Inc., Illumina, Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc. and others.
Request Free Sample Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=3999
Cancer Genomic Testing Market: Segmentation
Tentatively, the global cancer genomic testing market can be segmented on the basis of cancer type, end user and geography.
Based on cancer type, the global cancer genomic testing market is segmented as:
Breast Cancer
Lung Cancer
Blood Cancer
Liver Cancer
Stomach Cancer
Others
Based on distribution channel, the global cancer genomic testing market is segmented as:
Hospitals
Diagnostic Laboratories
Cancer Research Centers
Academic and Research Institutes
Specialized Clinics
Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=3999
Report on Cancer Genomic Testing includes the regional analysis for
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Cancer Genomic Testing Market: Key Players
Some of the key players operating in the global Cancer Genomic Testing Market are Myriad Genetics, Inc., CENTOGENE AG, Color Genomics, Quest Diagnostics, Inc., 23andMe Inc., Gene by Gene Ltd., Laboratory Corporation of America Holdings, Positive Bioscience, Bio Rad Laboratories Inc., Illumina, Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc. and others.
Comments
Post a Comment